Kinematic and Clinical Outcomes to Evaluate the Efficacy of a Multidisciplinary Intervention on Functional Mobility in Parkinson’s Disease

Raquel Bouça-Machado 1,2, Diogo Branco 3, Gustavo Fonseca 3, Raquel Fernandes 1, Daisy Abreu 1, Tiago Guerreiro 3, Joaquim J. Ferreira 1,2,4* and The CNS Physiotherapy Study Group

Introduction: Functional mobility (FM) is a concept that incorporates the capacity of a person to move independently and safely to accomplish tasks. It has been proposed as a Parkinson’s disease (PD) functional and global health outcome. In this study, we aimed to identify which kinematic and clinical outcomes changes better predict FM changes when PD patients are submitted to a specialized multidisciplinary program.

Methods: PD patients engaged in a pre-defined specialized multidisciplinary program were assessed at admission and discharge. Change from baseline was calculated for all kinematic and clinical outcomes, and Timed Up and Go (TUG) was defined as the primary outcome for FM. A stepwise multivariate linear regression was performed to identify which outcome measures better predict TUG changes.

Results: Twenty-four patients were included in the study. The changes in TUG Cognitive test, supervised step length, and free-living (FL) step time asymmetry were identified as the best predictors of TUG changes. The supervised step length and FL step time asymmetry were able to detect a small to moderate effect of the intervention (d values ranging from −0.26 to 0.42).

Conclusions: Our results support the use of kinematic outcome measures to evaluate the efficacy of multidisciplinary interventions on PD FM. The TUG Cognitive, step length, and FL step time asymmetry were identified as having the ability to predict TUG changes. More studies are needed to identify the minimal clinically important difference for step length and FL step time asymmetry in response to a multidisciplinary intervention for PD FM.

Keywords: Parkinson’s disease, functional mobility, outcome measures, gait, sensors, digital health, wearable, technology
INTRODUCTION

Functional mobility (FM) in Parkinson’s disease (PD) has been recently described as a person’s physiological ability to move independently and safely in a variety of environments in order to accomplish functional activities or tasks and to participate in activities of daily living at home, at work, and in the community (1, 2). From the early disease stage, PD patients experience limitations in their FM. With disease progression, these limitations are usually a major cause of disability and loss of independence (1).

FM has been reported as a useful outcome measure to understand patients’ overall health status, to address their daily needs related to mobility and social participation, and for monitoring, in a closer and more realistic fashion, the impact of disease progression and the effect of therapeutic interventions (2-4). The Timed Up and Go (TUG) test is a quick and easy-to-use test, specifically designed to measure FM that includes the three anchors of the concept, i.e., gait, balance, and postural transitions (2, 4, 5). Although it is the recommended tool for assessing FM in PD, other clinical tests are also used (2, 4, 5).

The development of technology-based objective measures (TOMs) and the possibility of using accurate and reliable quantitative information to evaluate PD patients’ gait enable a more objective and ecological (i.e., closer to patients’ real-life environment performance) perspective of patients’ FM (6, 7). A recent systematic review on outcome measures for assessing FM in PD included nine studies using kinematic gait parameters (2). The authors emphasize the important role of TOMs in monitoring FM throughout disease progression. They also highlight that despite the capacity of current devices to capture large amounts of data and a great diversity of parameters, the best kinematic parameters for assessing FM in PD remain to be defined (2).

In this study, we aimed to identify which kinematic and clinical outcome measures better predict FM changes when PD patients are submitted to a specialized multidisciplinary intervention.

METHODS

Study Design

A pragmatic prospective clinical study was conducted.

Objective

The objective of this study is to identify the kinematic and clinical outcome measures that better predict FM changes when PD patients are submitted to a specialized multidisciplinary intervention.

Participants

Study participants were recruited from CNS—Campus Neuroológico, a tertiary specialized movement disorders center in Portugal. Patients were eligible if they had a diagnosis of probable or clinically established PD (according to the International Parkinson and Movement Disorder Society criteria), had engaged in the specialized multidisciplinary program for parkinsonian patients at the CNS between January and September 2019, and if they agreed to participate. Exclusion criteria were the inability to adopt a standing position and/or to walk 3 m, postural instability compromising patient safety during the assessment, and the presence of cognitive deficits preventing understanding of the test instructions (according to a physiotherapist’s best judgment). The study was undertaken with the understanding and written consent of each participant, with the approval from the CNS Ethics Committee (ref. 10/19), and in compliance with national legislation and the Declaration of Helsinki. Participants were required to agree to all aspects of the study and were able to leave the study at any time.

Therapeutic Intervention

The specialized multidisciplinary program combined pharmacological and non-pharmacological therapies, including up to 20 h per week of individually tailored neurorehabilitation sessions of physiotherapy, occupational therapy, speech therapy, and cognitive training, according to the patient’s needs and rehabilitation goals. All rehabilitation sessions had a duration of 50 min.

The physiotherapy sessions aim to optimize independence, safety, and well-being, through movement rehabilitation, maximization of functionality, and minimization of secondary complications. The sessions focused on physical capacity training, gait, mobility, balance, sensorimotor coordination, and development, as well as teaching the patient and the usual caregivers adaptive strategies to enhance functionality.

Clinical Assessment Protocol

Patients were assessed in ON-state medication, by a trained health professional from each area, 48 h following admission and before discharge. The following parameters were collected:

- Demographic and clinical data;
- Disease severity: Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) total score and score from each sub-section (8), Hoehn and Yahr scale (8, 9), and Clinical and Patient Global Impression (CGI and PGI, respectively) of Severity and Change (10);
- Motor function: The Timed Up and Go (TUG) test with and without a cognitive and manual dual-task (5, 11, 12), Mini-BESTest (5, 13, 14), Five times Sit-to-Stand test (5 STS) (15, 16), and Schwab and England scale (17).

Analysis of Kinematic Data

Kinematic gait parameters were collected during the supervised motor assessments and for 3 days at the end of each assessment, in a free-living (FL) context. Each participant wore a single tri-axial accelerometer-based body-worn monitor (Axivity AX3) on their lower back (L5), programmed to capture raw data at 100 Hz with a dynamic range of ±8 g. Each subject performed two trials of each assessment, on each visit, and wore the AX3 for 3 days after each assessment.

In the supervised motor assessment, the physiotherapist used a mobile application to mark the start and end of each trial, which was synced with the AX3 internal clock. Departing from the segmentation of test trials provided by the application, we
manually adjusted the start and end of each test to match with the exact start and end of the movement and removed reported periods of pause. To extract meaningful data from the raw accelerometer signal, we started by resampling data to 100 Hz using linear interpolation, to mitigate known fluctuations of the sample rate (18). Afterward, offset was removed as well as machine noise using a second-order Butterworth low pass filter of 17 Hz (19). We focused the kinematic gait analysis in the study of spatiotemporal gait parameters. To extract gait parameters, the process was divided into two steps. First, we identified the walking bouts as the 2-s moving windows where summed standard deviations of tri-axial accelerations were above 0.1 (20). Then, an algorithm to detect initial contact (IC)/final contact (FC) points was applied, from which we calculated the gait parameters (21). A concurrent validity analysis of the reported number of steps (by the physiotherapist observing the trial) and the automatic detection revealed an intra-class correlation above 0.85.

In the FL context, where walking bouts are not previously annotated, a conservative approach was followed, meaning that high precision was sought (seeking that all detected bouts are indeed bouts), even if at the cost of lower recall (i.e., not all bouts are detected). Pre-processing of FL raw data followed a similar approach as the controlled assessment (resample and filtering). To improve walking bout detection in FL, we estimated an optimized scale of the Gaussian continuous wavelet transform (22) ("gaus2") and considered only the segments with a duration above 5 s and at least five detected ICs. Additionally, the first and last detected steps of each bout were trimmed off, given their specific transition characteristics. All remaining bouts (and steps) were subjected to extraction of parameters. An average per subject of 285.3 (SD = 175.2, min = 17, max = 622) walking bouts were extracted at the period of admission, and an average of 270.4 (SD = 129.0, min = 32, max = 647) were detected at the period of discharge, in the 3-day period. Gait parameters were calculated from the detected bouts as in the supervised motor assessment (21). Following previously published evidence in FL assessment, gait parameters were categorized in bouts from 5 to 15 s, 15 to 30 s, 30 to 60 s, and longer than 60 s (21). Our implementation of the extraction of gait parameters from walking bouts is available and open-sourced (https://github.com/Gustavo-SF/gait_extractor).

**Statistical Analysis**

Descriptive statistics were used for demographic, clinical, and therapeutic data. Continuous outcomes were defined as change from baseline for all the previously mentioned outcome measures and presented as a mean ± standard deviation (SD).

Our main goal was to explore the best predictors of changes in TUG (the gold standard for evaluating FM in PD). To do this, stepwise multiple linear regression analyses were performed using different independent variables (clinical measures, gait parameter assessment during the 10-m walk test, and FL gait parameters analyzed in bouts longer than 60 s). To validate the analysis, the normal distribution of residuals and the absence of multicollinearity were ascertained.

Only the outcome measures able to detect an effect of the intervention were used in the main analysis. This required an assessment, before our main analysis, of the existence of an intervention effect and the ability of the included outcome measures to detect it. We started by studying normality, using the Kolmogorov–Smirnov and the Shapiro–Wilk tests, and applying the paired sample T-test and the Wilcoxon S-R test to each parameter to analyze the effects of the program (statistical significance was set at \( p < 0.05 \)). Cohen’s \( d \) was employed as a measure of effect size to assess small (0.20–0.49), medium (0.50–0.80), and large (>0.80) effects (23).

We also performed some exploratory analysis to better understand how the outcome measures, selected as best predictors of FM changes, behave if used as the primary outcome in a future study. Power analysis and sample size calculations were performed using G*Power software, to understand how many participants would be needed to enable statistically significant results (80% power) if the TUG test or one of the outcome measures able to detect at least a small effect size were used as the primary outcome in a clinical study. A significance level of \( \alpha = 0.05 \) and a power \( 1 – \beta = 0.80 \) were assumed. To explore the variability of the different gait parameters, a power analysis assuming 10, 20, and 30% of change from baseline and using the mean SD of change from baseline was calculated for each parameter. The choice of the 30% magnitude of effect was based on the minimal clinically important difference (MCID) reported for the TUG test, the recommended measurement tool for assessing FM in PD. It also used a 20% magnitude of effect, based on MCID reported for spatial asymmetry in a previous study evaluating the effect of rehabilitation training on PD patients’ gait parameters (25.76%) (24).

Additionally, and also as an exploratory analysis, we applied paired sample t-test and the Wilcoxon S-R test to the different bout lengths of FL assessment to investigate how the length of the bout contributes to the existence of a statistically significant difference between admission and the end of the program (significance was achieved with a \( p \)-value < 0.05).

**RESULTS**

**Cohort Demographic and Clinical Data**

Of the 54 PD patients who engaged in a CNS specialized multidisciplinary program between January and September 2019, a total of 24 participants were included in this study. The reasons for exclusion were lack of collaboration/missing data (27.8%, \( n = 15 \)), motor inability to perform the assessments (18.5%, \( n = 10 \)), and the presence of cognitive impairment and behavioral disturbances (9.3%, \( n = 5 \)). Eight patients did not perform the FL assessment due to behavioral disturbances and refusal of the belt that supports the trunk sensor. Some of the included patients did not fulfill all the clinical assessment battery due to fatigue and lack of collaboration. The mean age of the participants was 73.0 ± 8.0 years, and 66.7% (\( n = 16 \)) were men. At admission, the average disease duration was 8.0 ± 5.1 years, with a mean Hoehn and Yahr stage of 2.3 ± 0.9 and a mean MDS–UPDRS motor score of 39.4 ± 12.8. All patients were under antiparkinsonian treatment, and 50% (\( n = 12 \)) had motor fluctuations.
Patients’ demographic and clinical characteristics at admission and discharge are summarized in Table 1. Table 2 summarizes the changes in gait parameter values in both assessment conditions.

All the clinical and gait parameters from the supervised assessment showed an improvement, having reached statistical significance (p ≤ 0.05) in the MDS-UPDRS parts I, II, III, and total score; in the 5 STS test; and the following gait parameters: gait velocity, stride and step velocity, step length, and swing time asymmetry (Tables 1, 2). The improvement in the TUG test did not reach statistical significance, contrary to gait velocity, stride and step velocity, step length, and swing time asymmetry measured during the test. In FL conditions, an improvement was detected when the analysis was made using bouts of at least 30 s. Specifically, the following gait parameters have reached statistical significance (p ≤ 0.05): cadence, step time, stance time, swing time, and double support time when data was analyzed in bouts of 30–60 s and stance, swing, and double support phases when bouts of more than 60 s were used in the analysis (Table 2 and Appendix 1).

Prediction of FM Changes
The stepwise multivariate linear regression analysis, between TUG (dependent variable) and the clinical outcome measures able to detect an effect, indicated the TUG Cognitive as the best variable to predict TUG changes (adjusted R² = 0.72). The same analysis using supervised and FL kinematic gait parameters as independent variables identified step length (adjusted R² = 0.53) and step time asymmetry (adjusted R² = 0.51) as the best predictors of TUG changes for each assessment condition (Table 3).

Responsiveness to Intervention
The TUG test was able to detect a small effect size (d = −0.24) of the intervention (Appendix 2).
From the supervised assessment, the outcome measures able to detect a large effect size were the STS Normal (d = −1.46) and Fast (d = −1.47) and the MDS-UPDRS total score (d = −0.87).
From the FL assessment, the outcome parameters with higher sensitivity to the intervention were stance time asymmetry (d = −0.38), stride length (d = 0.37), double support time variability (d = −0.37), and step length (d = 0.36).

Sample Size Calculation
A power analysis was performed to understand how many participants would be needed to enable statistically significant results (80% power), if the TUG test or one of the outcome measures able to detect at least a small effect size was used as

### TABLE 1 | Demographical and clinical characteristics of the sample.

| Demographic features (n = 24)                      |
|---------------------------------------------------|
| Age (Mean, SD)                                    | 73.04 ± 8.00 |
| Male sex [% (n)]                                  | 66.67% (16)  |
| Body mass index (BMI) (Mean, SD)                  | 25.79 ± 3.90 |
| Time since diagnosis (Mean, SD)                   | 8.04 ± 5.10  |
| Presence of motor fluctuations [% (n)]            | 50% (12)     |

| Clinical data [Mean (SD), (Range)]                |
|---------------------------------------------------|
| MDS-UPDRS I (range 0–52; n = 19; ↓)               | 13.96 ± 7.09 |
| MDS-UPDRS II (range 0–52; n = 19; ↓)              | 17.18 ± 9.24 |
| MDS-UPDRS III (range, 0–132; n = 19; ↓)           | 39.36 ± 12.77|
| MDS-UPDRS IV (range 0–24; n = 19; ↓)              | 1.95 ± 2.82  |
| MDS-UPDRS Total (range 0–260; n = 19; ↓)          | 72.45 ± 25.75|
| Hoehn and Yahr stage (range 1–5; n = 24; ↓)       | 2.30 ± 0.93  |
| Schwab and England (range 0–100; n = 24; ↑)       | 73.75 ± 16.37|
| TUG Normal (n = 24; ↓)                            | 13.36 ± 7.27 |
| TUG DT Cognitive (n = 23; ↓)                      | 17.22 ± 10.42|
| TUG DT Manual (n = 19; ↓)                         | 12.80±5.21   |
| Mini-best (range 0.28; n = 19; ↑)                 | 20.19±3.97   |
| 5 Sit-to-Stand Normal (n = 22; ↓)                 | 19.36±6.99   |
| 5 Sit-to-Stand Fast (n = 22; ↓)                   | 17.56±4.91   |

| Severity (Baseline) Change (Discharge)            |
|---------------------------------------------------|
| Clinical Global Impression (n = 24; ↓)            | 4.0 ± 0.83  |
| Patient Global Impression (n = 24; ↓)             | 3.91 ± 1.02 |

↑ - a higher score means an improvement, ↓ - a lower score means an improvement. The paired-samples T-test and the Wilcoxon S-R tests were applied to investigate the existence of a statistically significant difference between admission and the end of the program. Significance was achieved with a p-value < 0.05. Bold values is to highlight the outcomes that reached statistical significance.
### TABLE 2 | Admission (i.e., baseline) and change from baseline values (i.e., mean post-pre assessment difference and respective percentage value) of gait parameters in the supervised and free-living assessments.

| Gait parameters supervised assessment | Supervised assessment | Free-living assessment |
|--------------------------------------|-----------------------|------------------------|
|                                      | TUG normal            | 10-meter walk test      | Bouts longer than 60 s |
|                                      | Admission (i.e., baseline) | Change from baseline | p-value | Admission (i.e., baseline) | Change from baseline | p-value | Admission (i.e., baseline) | Change from baseline | p-value |
| Gait velocity (m/s)                  | 0.71 ± 0.19           | 0.06 ± 0.13 (5.5%)     | 0.037    | 0.82 ± 0.21             | 0.05 ± 0.18 (6.1%)    | 0.188    | 0.59 ± 0.14             | 0.04 ± 0.13 (6.8%)    | 0.209    |
| Cadence (steps/min)                  | 118.77 ± 12.00        | 1.94 ± 13.02 (1.6%)    | 0.472    | 119.92 ± 13.72          | 3.66 ± 12.95 (3.1%)   | 0.180    | 104.93 ± 10.33          | −0.92 ± 9.17 (0.9%)   | 0.695    |
| Stride length (m)                    | 0.78 ± 0.18           | 0.06 ± 0.14 (7.7%)     | 0.057    | 0.89 ± 0.20             | 0.04 ± 0.17 (4.5%)    | 0.204    | 0.69 ± 0.16             | 0.05 ± 0.13 (7.2%)    | 0.160    |
| Stride velocity (m/s)                | 0.71 ± 0.19           | 0.06 ± 0.13 (5.5%)     | 0.033    | 0.82 ± 0.21             | 0.05 ± 0.18 (6.1%)    | 0.225    | 0.59 ± 0.14             | 0.04 ± 0.13 (6.8%)    | 0.202    |
| Step length (m)                      | 0.39 ± 0.09           | 0.03 ± 0.07 (7.7%)     | 0.049    | 0.45 ± 0.10             | 0.02 ± 0.08 (4.4%)    | 0.230    | 0.34 ± 0.08             | 0.02 ± 0.06 (5.9%)    | 0.171    |
| Step velocity (m/s)                  | 0.72 ± 0.19           | 0.06 ± 0.13 (8.3%)     | 0.037    | 0.82 ± 0.21             | 0.05 ± 0.18 (6.1%)    | 0.182    | 0.60 ± 0.14             | 0.04 ± 0.13 (6.7%)    | 0.220    |
| Stance phase (% of gait cycle)       | 75.26 ± 1.36          | −0.11 ± 1.35 (0.2%)    | 0.708    | 75.35 ± 0.49            | −0.18 ± 1.32 (0.2%)   | 0.514    | 75.11 ± 0.55            | 0.20 ± 0.36 (0.3%)    | 0.047    |
| Swing phase (% of gait cycle)        | 24.74 ± 1.36          | 0.11 ± 1.35 (0.5%)     | 0.708    | 24.65 ± 0.49            | 0.18 ± 1.32 (0.7%)    | 0.514    | 24.89 ± 0.55            | −0.20 ± 0.36 (0.8%)   | 0.047    |
| Double support phase (% of gait cycle)| 25.33 ± 1.33          | −0.13 ± 1.36 (0.5%)    | 0.643    | 25.34 ± 0.51            | −0.19 ± 1.27 (0.8%)   | 0.476    | 25.11 ± 0.54            | 0.19 ± 0.36 (0.6%)    | 0.050    |
| Step time (seconds)                  | 0.56 ± 0.06           | −0.02 ± 0.06 (3.6%)    | 0.893    | 0.55 ± 0.07             | −0.01 ± 0.06 (1.8%)   | 0.525    | 0.60 ± 0.06             | 0.002 ± 0.06 (0.3%)   | 0.896    |
| Stance time (seconds)                | 0.84 ± 0.09           | −0.01 ± 0.09 (1.2%)    | 0.800    | 0.83 ± 0.10             | −0.01 ± 0.09 (1.2%)   | 0.589    | 0.90 ± 0.09             | 0.004 ± 0.09 (0.4%)   | 0.845    |
| Swing time (seconds)                 | 0.28 ± 0.04           | 0.002 ± 0.04 (0.7%)    | 0.828    | 0.27 ± 0.03             | −0.001 ± 0.03 (3.7%)  | 0.902    | 0.30 ± 0.03             | −0.001 ± 0.03 (0.3%)  | 0.930    |
| Double support time (seconds)        | 0.28 ± 0.03           | −0.004 ± 0.03 (1.4%)   | 0.561    | 0.28 ± 0.03             | −0.004 ± 0.03 (1.4%)  | 0.916    | 0.30 ± 0.03             | 0.004 ± 0.03 (1.3%)   | 0.583    |
| Stride time variability (% CV)       | 0.07 ± 0.04           | −0.004 ± 0.04 (5.7%)   | 0.636    | 0.04 ± 0.02             | −0.001 ± 0.03 (2.5%)  | 0.880    | 0.12 ± 0.03             | −0.01 ± 0.04 (8.3%)   | 0.393    |
| Step length variability (% CV)       | 0.05 ± 0.02           | −0.003 ± 0.03 (8%)     | 0.516    | 0.03 ± 0.01             | 0.004 ± 0.02 (13.3%)  | 0.260    | 0.06 ± 0.01             | 0.003 ± 0.02 (5%)     | 0.446    |
| Step time variability (% CV)         | 0.05 ± 0.03           | −0.002 ± 0.03 (4%)     | 0.730    | 0.03 ± 0.02             | 0.0004 ± 0.02 (1.3%)  | 0.930    | 0.09 ± 0.02             | −0.01 ± 0.03 (11.1%)  | 0.210    |
| Step velocity variability (% CV)     | 0.11 ± 0.04           | −0.008 ± 0.04 (7.3%)   | 0.352    | 0.06 ± 0.02             | 0.01 ± 0.04 (16.7%)   | 0.163    | 0.13 ± 0.03             | 0.004 ± 0.03 (3.1%)   | 0.657    |
| Stance time variability (% CV)       | 0.06 ± 0.03           | −0.005 ± 0.03 (8.3%)   | 0.384    | 0.03 ± 0.02             | −0.002 ± 0.02 (6.7%)  | 0.665    | 0.10 ± 0.03             | −0.01 ± 0.03 (10%)    | 0.340    |

(Continued)
### TABLE 2 | Continued

| Gait parameters supervised assessment | Supervised assessment | Free-living assessment |
|--------------------------------------|-----------------------|-----------------------|
|                                      | TUG normal            | 10-meter walk test     | Bouts longer than 60 s |
|                                      | Admission             | Change from baseline  | Admission             | Change from baseline  | p-value | Admission             | Change from baseline  | p-value |
| Swing time variability (% CV)        | 0.03 ± 0.02           | −0.006 ± 0.02         | 0.884                 | 0.02 ± 0.01           | 0.001 ± 0.02         | 0.862 | 0.05 ± 0.02           | −0.01 ± 0.02         | 0.216 |
| Double support variability (% CV)   | 0.03 ± 0.02           | −0.003 ± 0.02         | 0.455                 | 0.02 ± 0.01           | 0.0002 ± 0.01        | 0.994 | 0.05 ± 0.02           | −0.01 ± 0.02         | 0.163 |
| Stride time asymmetry (% CV)        | 0.01 ± 0.01           | 0.002 ± 0.02          | 0.959                 | 0.01 ± 0.01           | −0.001 ± 0.01        | 0.584 | 0.01 ± 0.004          | −0.001 ± 0.01        | 0.300 |
| Step time asymmetry (% CV)          | 0.02 ± 0.02           | 0.005 ± 0.02          | 0.262                 | 0.03 ± 0.02           | 0.003 ± 0.02         | 0.496 | 0.03 ± 0.02           | −0.01 ± 0.02         | 0.318 |
| Stance time asymmetry (% CV)        | 0.02 ± 0.02           | −0.003 ± 0.02         | 0.622                 | 0.02 ± 0.02           | −0.003 ± 0.02        | 0.420 | 0.02 ± 0.01           | −0.01 ± 0.02         | 0.153 |
| Swing time asymmetry (% CV)         | 0.02 ± 0.01           | 0.008 ± 0.02          | 0.036                 | 0.02 ± 0.01           | −0.003 ± 0.02        | 0.423 | 0.02 ± 0.01           | −0.01 ± 0.02         | 0.196 |
| Step length asymmetry (% CV)        | 0.03 ± 0.02           | −0.002 ± 0.02         | 0.605                 | 0.02 ± 0.02           | 0.0002 ± 0.02        | 0.959 | 0.02 ± 0.01           | −0.002 ± 0.01        | 0.504 |

The paired-samples T-test and the Wilcoxon S-R tests were applied for each parameter to investigate the existence of a statistically significant difference between admission and the end of the program (statistical significance was achieved with p-value < 0.05). Bold values is to highlight the outcomes that reached statistical significance.
a primary outcome in a clinical study. Appendix 2 summarizes the sample size calculations assuming 10, 20, and 30% change from baseline.

**DISCUSSION**

Although this study was not designed to conclude on efficacy, the results obtained suggest an overall improvement (Tables 1, 2). This enables us to identify the best predictors of FM changes when PD patients are submitted to a specialized multidisciplinary program. It also enables performing other exploratory analyses to better understand how the outcome measures behave if used as primary outcomes in future studies.

From the pool of outcome measures able to detect at least a small effect size of the intervention, those identified as the best predictors of TUG changes were the TUG Cognitive, step length, and step time asymmetry.

**Clinical Assessment**

The TUG Cognitive test was the clinical parameter with the best ability to predict TUG changes. This can be explained because the TUG Cognitive is a modified version of the TUG (i.e., it adds a cognitive task to the motor task) (25, 26). Since daily activities frequently require motor and cognitive tasks to be carried out simultaneously, this version of the test may give a more realistic perspective of the patients' FM. However, as it is only a modified version of the same test, some major limitations remain (e.g., it is limited to patients without significant postural instability and is subject to learning effects).

The Mini-BESTest test was not sensitive to the intervention, and the observed differences were not statistically significant. However, this is a very complete clinical test that includes the assessment of static and dynamic balance (i.e., biomechanical constraints, verticality/stability limits, anticipatory postural adjustments, postural responses, sensory orientation, and stability in gait) and the TUG Cognitive test itself (5, 13, 14). Although not formally validated to measure FM, this instrument provides a more complete approach to the three anchors of the concept, i.e., gait, balance, and postural transitions (5, 13, 14). We believe that future studies should clarify the Mini-BESTest's suitability to assess FM changes.

**Clinical vs. Kinematic Assessment**

Our results identified step length and step time asymmetry as the gait parameters with the best ability to predict TUG (and FM) changes, in supervised and FL conditions, respectively. Compared with the TUG, both showed higher responsiveness to change.

FM is a major source of disability for PD patients and requires an individualized and complex management approach that strongly depends on the information about the actual state of the patients in their daily lives (1). Although the TUG remains the gold standard for assessing PD FM, as is the case for all traditional clinical scales, it presents some limitations that can be overcome by the use of TOMs (27).

To optimize the accuracy of clinical evaluation, evidence suggests that patients should focus on the goal of the task asked and not on the movement required to achieve it. This is hampered when a reassessment using the TUG test takes place after a multidisciplinary program. During the physiotherapy sessions of the program, patients usually learn safety strategies to apply during walking and postural transitions that require being focused on the movement while doing it. Many of these strategies are applied during the TUG test, thereby hindering its ability to detect an improvement in patients' FM (27).

There is increasing evidence that TOMs may improve the sensitivity, accuracy, reproducibility, and feasibility of data capture, detecting improvements that the clinical tests are not able to find (6). Previous studies reported a greater sensitivity of TOMs, over the traditional clinical scales, in differentiating the gait and turning of PD patients from healthy controls (27).

The use of outcome measures of higher sensitivity and accuracy, which can predict TUG changes (step length and step time asymmetry), may help obtain a more complete and objective evaluation of patients' FM limitations and thereby favoring more personalized clinical decision making (6, 28). In the research field, the use of standardized outcome measures, with high responsiveness to change and low variability, not only enables better interpretation and discussion of research findings but also avoids unnecessary increases in complexity, duration, and financial expenses of studies (6).

Despite the benefits associated with the use of TOMs for assessing FM, from our experience, they also have some
limitations. The currently available sensors, although smaller and lighter, remain too intrusive, leading patients to reject their use. Also, in PD patients with behavioral changes, the use of sensors may not be possible. One of the patients was excluded from the FL analysis, after having thrown away the sensors during an episode of delirium.

Supervised vs. Free-Living Assessment
According to our results, the responsiveness of the outcomes and their ability to predict TUG changes differ depending on the type of assessment.

There is a growing awareness that, depending on the assessment conditions, the results related to gait and postural transitions can differ substantially, with a weak association between the results in both scenarios having been reported (28, 29). Many factors can contribute to these differences: (1) the clear and standardized environment in supervised assessment, in the absence of distractions, emphasizes a measure of someone’s best, rather than their usual performance; (2) FL conditions, with narrow corridors, variable lighting, obstacles, etc., forces continuous gait adaptations, inducing large variability and asymmetry in walking patterns; (3) movements in a supervised assessment are triggered by instruction, while FL movements are usually self-initiated, goal-directed, and embedded in a rich behavioral environment; and (4) patients frequently improve their performance when they know that they are being evaluated (21, 28, 29).

In the FL context, gait parameters, and therefore FM, may be influenced not only by physical characteristics but also by ongoing environmental and cognitive challenges (29). Variability and asymmetry-related parameters are especially sensitive to behavioral and environmental factors, better reflecting patients’ interaction with the context and their ability to adapt gait patterns (28, 29). We hypothesize that this may be one of the causes of step time asymmetry identified as the FL kinematic gait parameter, which better predicts TUG changes. Although it has only captured a small effect size of the intervention, having a high ecological validity, FL step time asymmetry seems to provide a more realistic picture of the impact of the disease in PD FM, whereby even small changes should be valued (27).

Length of Walking Bouts
We performed an exploratory analysis to understand how FL gait parameters behave when different bout lengths were used in the analysis. According to our results, there appears to be a link between the ability to capture an improvement and the length of the bout. The longer the walking bouts, the higher the velocity and length of stride/step and the lower the cadence, variability, and asymmetry.

A previous study exploring the impact of environment and bout length in PD patients’ gait reached similar conclusions, i.e., the longer the bouts, the higher the increase in step velocity, step length and swing time variability and the lower the variability and asymmetry of gait. The authors also reported that the parameters analyzed in longer bouts were more similar to those measured in a supervised environment (21).

Walking bout length is influenced by the type of environment and activity patients are engaged in (21). Currently, the most suitable length of walking bouts used in FL analysis is not established (21). The majority of studies investigating gait characteristics in FL conditions use bouts longer than 60 s. However, it has been reported that PD patients in FL conditions more often perform a large number of very short bouts (≤10 s) than prolonged bouts (21). According to the literature, bouts of 30–60 s usually represent indoor activities, while bouts > 120 s correspond to walking outdoors. Only bouts with at least 30–60 s were able to discriminate PD patients from healthy controls (21).

Limitations
This study presents two major limitations: a small sample size (n = 24) and high heterogeneity in the included population. We believe that these aspects may overestimate the variability of the measurement tools, influencing the power calculations. We expect that future studies with a large and less heterogeneous population will need a smaller sample size. As an open non-controlled study, we hypothesize that in future larger, controlled trials, the detected effect size will be smaller. However, since this was not an efficacy study (due to the absence of a control group) and an improvement was observed, despite these limitations, we believe that our results are informative and important for the PD field. Also, we believe that the use of broad inclusion criteria in this study not only did not interfere with its aims but also better mimics the real scenario of the intervention and assessments, increasing its external validity. To minimize the impact, the study was conducted in a single tertiary care center.

According to our results, the TUG test did not achieve a statistically significant improvement. However, some of the gait parameters (including step length) not only reached a statistically significant result but also showed a higher sensitivity to change. Since all other results point to an improvement at the end of the program, we believe that this difference may be explained by the greater accuracy and sensitivity to change of TOMs when compared to the traditional clinical scales. A previous study has already highlighted this potential problem, highlighting that the validation of TOMs is often based on their correlation with validated clinical measures and that results may be undesirable, due to the superior capacity of TOMs for capturing the phenomena of interest (30).

CONCLUSION
Although we cannot attribute the observed improvements to the specialized multidisciplinary program, our results suggest a methodological approach for identifying outcome measures to assess FM changes, in response to a therapeutic intervention.

From all the outcome measures included in the study, only the TUG Cognitive, step length, and FL step time asymmetry were identified as having the ability to predict TUG changes. The kinematic parameters seem to present higher responsiveness to change when compared with the traditional clinical tests. According to our results, supported by published evidence, the longer the bouts, the higher the sensitivity of detecting an improvement.
Our results support the use of kinematic assessments in evaluating the effect of multidisciplinary interventions in PD FM. The FL step time asymmetry seems a very promising outcome measure to assess FM in PD. Nevertheless, there are some aspects of FL assessments that need to be improved, such as establishing the best data collection protocol and developing less intrusive sensors.

To improve the interpretation of results of responsiveness to change in a complex and fluctuating disease such as PD, it is necessary to clarify the variation of gait parameters in the absence of pharmacological and non-pharmacological therapeutic interventions. This requires repeating the assessment protocol in ON- and OFF-state medication and several therapeutic interventions. This requires repeating the assessment in the absence of pharmacological and non-pharmacological intrusive sensors.

Aspects of FL assessments that need to be improved, such as evaluating the effect of multidisciplinary interventions in PD FM.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available in the supplementary material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by CNS Ethics Committee. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**REFERENCES**

1. Bouça-Machado R, Maetzler W, Ferreira JJ. What is functional mobility applied to Parkinson’s disease? J Parkinsons Dis. (2018) 8:121–30. doi: 10.3233/JPD-171233
2. Bouça-Machado R, Duarte GS, Patriarca M, Castro Caldas A, Alarcão J, Fernandes RM, et al. Measurement instruments to assess functional mobility in Parkinson’s disease: a systematic review. Movement Disord Clin Pract. (2020) 7:129–39. doi: 10.1002/mdc3.12874
3. Bhidayasiri R, Martínez-Martín P. Clinical assessments in Parkinson’s disease. Int Rev Neurobiol. (2017) 132:129–82. doi: 10.1016/bs.irn.2017.01.001
4. Verheyden G, Kampshoff CS, Burnett ME, Cashell J, Martinelli L, Nicholas A, et al. Psychometric properties of 3 functional mobility tests for people with Parkinson disease. Phys Ther. (2014) 94:230–9. doi: 10.2522/ptj.20130141
5. Bloem BR, Marinus J, Almeida Q, Dibble L, Nieuwboer A, Post B, et al. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. (2008) 23:2129–70. doi: 10.1002/mds.22430
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. (1967) 17:427–42. doi: 10.1212/WNL.17.5.427
7. Martínez-Martin P, Rojo-Abuin JM, Rodríguez-Violante M, Serrano-Dueñas M, Garretto N, Martínez-Castrillo JC, et al. Analysis of four scales for global severity evaluation in Parkinson’s disease. NPJ Parkinson Dis. (2016) 2:16007. doi: 10.1038/npjparkdis.2016.7
8. Poledri D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. (1991) 39:142–8. doi: 10.1111/j.1532-5415.1991.tb01616.x
9. Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the timed ‘up, & go’ test in people with Parkinson disease. Phys Ther. (2001) 81:810–8. doi: 10.2522/ptj/81.2.810
10. Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the balance evaluation systems test: the mini-BESTest. J Rehabil Med. (2013) 45:323–31. doi: 10.2340/16501977-0537
11. Leddy AL, Crowner BE, Earhart GM. Utility of the mini-BESTest, BESTest, and TBESTest sections for balance assessments in individuals with Parkinson disease. J Neurol Phys Ther. (2011) 35:90–7. doi: 10.1097/NPT.0b013e31821a620c

**AUTHOR CONTRIBUTIONS**

RB-M and JF contributed to the conception and design of the study. The CNS physiotherapy study group contributed to the participants’ recruitment and assessments. RB-M performed the assessments and performed the statistical analysis. DB, GF, and TG analyzed kinematic data. RB-M and JF drafted the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

**FUNDING**

The authors would like to acknowledge the Fundação para a Ciência e a Tecnologia (FCT) (SFRH/BD/120773/2016 to RB-M; SFRH/BD/144242/2019 to DB, UIDB/00408/2020 and UIDP/00408/2020 to LASIGE).

**COLLABORATORS (CNS PHYSIOTHERAPY STUDY GROUP)**

Daniela Guerreiro, Verónica Caniça, Francisco Queimado, Pedro Nunes, Alexandra Saíde, Laura Antunes, Joana Alves, Beatriz Santos, Inês Lousada, Maria A. Patriarca, Patricia Costa, Raquel Nunes e Susana Dias.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2021.637620/full#supplementary-material
15. Mayhew T, Rothstein J. Measurement of muscle performance with instruments. *Percept Mot Skills.* (1995) 80:163–6. doi: 10.2466/pms.1995.80.1.163
16. Duncan RP, Leddy AL, Earhart GM. Five times sit-to-stand test performance in Parkinson’s disease. *Arch Phys Med Rehabil.* (2011) 92:1431–6. doi: 10.1016/j.apmr.2011.04.008
17. Bjornestad A, Tynnesen OR, Larsen JP, Alves G. Reliability of three disability scales for detection of independence loss in Parkinson’s disease. *Parkinsons Dis.* (2016) 2016:1941034. doi: 10.1155/2016/1941034
18. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, et al. Large scale population assessment of physical activity using wrist worn accelerometers: the UK biobank study. *PLoS ONE.* (2017) 12:e0169649. doi: 10.1371/journal.pone.0169649
19. Hickey A, Del Din S, Rochester L, Godfrey A. Detecting free-living steps and walking bouts: validating an algorithm for macro gait analysis. *Physiol Meas.* (2017) 38:N1–N15. doi: 10.1088/1361-6579/38/1/N1
20. Lyons GM, Culhane KM, Hilton D, Grace PA, Lyons D. A description of an accelerometer-based mobility monitoring technique. *Med Eng Phys.* (2005) 27:497–504. doi: 10.1016/j.medengphy.2004.11.006
21. Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait characteristics in ageing and Parkinson’s disease: impact of environment and ambulatory bout length. *J Neuroeng Rehabil.* (2016) 13:46. doi: 10.1186/s12984-016-0154-5
22. Pham MH, Elshehabi M, Haertner L, Del Din S, Srulijes K, Heger T, et al. Validation of a step detection algorithm during straight walking and turning in patients with Parkinson’s disease and older adults using an inertial measurement unit at the lower back. *Front Neurol.* (2017) 8:1–9. doi: 10.3389/fneur.2017.00457
23. Aron, A. *Statistics for Psychology* (2003).
24. Serrao M, Chini G, Caramanico G, Bartolo M, Castiglia SF, Ranavolo A, et al. Prediction of responsiveness of gait variables to rehabilitation training in Parkinson’s disease. *Front Neurol.* (2019) 10:826. doi: 10.3389/fneur.2019.00826
25. Campbell CM, Rowe JL, Ciol MA, Shumway-cook A. The effect of cognitive demand on timed up and go performance in older adults with and without Parkinson disease. *Neurol Rep.* (2003) 27:2–7. doi: 10.1097/01253086-200327010-00002
26. Hofheinz M, Schusterschitz C. Dual task interference in estimating the risk of falls and measuring change: a comparative, psychometric study of four measurements. *Clin Rehabil.* (2010) 24:831–42. doi: 10.1177/0269215510367993
27. Del Din S, Godfrey A, Mazzà C, Lord S, Rochester L. Free-living monitoring of Parkinson’s disease: lessons from the field. *Mov Disord.* (2016) 31:1293–313. doi: 10.1002/mds.26718
28. Warmerdam E, Hausdorff JM, Aтраsaei A, Zhou Y, Mirelman A, Aminian K, et al. Long-term unsupervised mobility assessment in movement disorders. *Lancet Neurol.* (2020) 19:462–70. doi: 10.1016/S1474-4422(19)30397-7
29. Rispens SM, Van Dieën JH, Van Schooten KS, Lizama LE, Daffertshofer A, Beek PJ, et al. Fall-related gait characteristics on the treadmill and in daily life. *J Neuroeng Rehabil.* (2016) 13:12. doi: 10.1186/s12984-016-0118-9
30. Artusi CA, Mishra M, Latimer R, Vizcarra JA, Lopiano L, Maetzler W, et al. Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. *Park Relat Disord.* (2018) 46:553–6. doi: 10.1016/j.parkreldis.2017.07.022

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Bouça-Machado, Branco, Fonseca, Fernandes, Abreu, Guerreiro, Ferreira and The CNS Physiotherapy Study Group. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*